You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Administrative Supplement to restore fee funds

    SBC: AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC.            Topic: NINDS

    Project Summary Traumatic brain injuryTBIcauses detrimental behavioral dysfunctions and brain neurodegeneration butunfortunatelythere currently is no effective pharmaceutical TBI treatmentThe underlying PhaseSTTR grant is to develop a new class of TBI drugs that inhibit the protease cathepsin BGenetically deleting the cathepsin B gene in mice results in substantial behavioral and pathology improve ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. A novel RF coil and incubator for reducing acoustic noise in neonatal MRI

    SBC: NeoView, Inc.            Topic: NICHD

    PROJECT SUMMARY In this Phase I Small Business Technology TransferSTTRprojecta team of researchers at Cincinnati Childrenandapos s Hospital Medical CenterCCHMCwill work with the engineering team at NeoViewIncto design and build novel body coil and incubator prototypes for aTesla Neonatal Intensive Care UnitNICUMRI systemThese components will play a central role in NeoViewandapos s neonatal MRI pro ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. A Novel Therapeutic that Harnesses MIcrotubules to Enhance Corneal Wound Healing Following an Alkaline Burn

    SBC: MICROCURES INC            Topic: NEI

    The cornea is one of the most important tissues in the eye and its transparency is critical for good visual function in humansCorneal tissue injuries are the most common everyday issue for practicing ophthalmologists and can run the gamut in severityIn severe modelssuch as corneal alkaline burnsextensive healing is needed and often the burn victim is left with reduced visual acuityHealing of large ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Robot-Assisted Cognitive Training for Socially Isolated Older Adults with Mild Cognitive Impairment

    SBC: Applied Universal Dynamics, Corp.            Topic: NIA

    Project Summary Abstract This project will develop a Socially Assistive RobotSARto provide cognitive trainingin the form of learning to play the pianoto improve cognitive functioning and reduce feelings of loneliness in socially isolated older adultsThe SAR will administer cognitive training via guided practice on a set of standard piano lesson tasks designed to reflect particular cognitive functi ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Making Standing Balance The Fifth Vital Sign in Clinical Settings

    SBC: BERTEC CORP            Topic: NIA

    Falls are a significant source of early morbidity and mortality in the aging populationyet the neurologicalsensoryand motor changes that lead to increased fall risk often escape early identification and interventionVital signs are commonly used in clinical settings to assess the cardiovascular systemblood pressureheart rateimmune systembody temperatureand the respiratory systemrespiratory rateto e ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Astrocyte activation by small-molecule ADORA3 agonists: a novel therapy for Alzheimer's disease

    SBC: ASTROCYTE PHARMACEUTICALS INC.            Topic: NIA

    PROJECT SUMMARY Alzheimerandapos s diseaseADis an area of significant unmet need that creates a national burden of$billion annuallyAD is the leading cause of dementiaaffectingof Americans over the age ofDemographic shifts and the age related nature of AD will soon place this disease as the costliest health care expenditure in the U Swith a projected impact of $trillion per year byCurrent therapies ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. A practical platform for in-home remote monitoring of cognitive-frailty

    SBC: BIOSENSICS LLC            Topic: NIA

    AbstractCognitive frailtythe combined presence of physical frailty and cognitive impairmentis a strong and independent predictor of cognitive declineThe International Association of Gerontology and Geriatrics and the International Academy on Nutrition and Aging have recommended the use of cognitive frailty assessment to track the progression of mild cognitive impairmentMCItowards dementiaAlzheimer ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.

    SBC: ARCHER PHARMACEUTICALS, INC.            Topic: NIA

    Pathological hallmarks of Alzheimerandapos s diseaseADinclude extracellular deposits of Apeptidesintraneuronal aggregates of abnormally phosphorylated tau protein and neuroinflammationMost proposed AD disease modifying therapies have focused on strategies that reduce brain Aamyloid or tau pathological accumulationHoweversuch approaches have been unsuccessful in late stage AD clinical trials and ma ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD

    SBC: MASSACHUSETTS GENERAL HOSPITAL            Topic: NIA

    Abstract Overmillion Americans are currently affected by Alzheimerandapos s diseaseADwith an economic burden estimated at andgt$billion year inthat is projected increase at least four fold over next several decadesIn spite of the dearth of pharmacological options to modify the course of the disease at presentthe field has developed accurate biomarkers that demonstrate that the pathology of AD is p ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1

    SBC: VELUM INC            Topic: NIA

    There is a world wide twin epidemic of obesity and TypeDiabetesT Dwith an urgent need to find effective new drug treatments for inducing weight lossStable derivatives of the endogenous glucoregulatory hormoneglucagon like peptideGLPare in clinical use for the treatment of T D but are of equally great interest as an emerging treatment of obesity and of age related neurodegenerative conditions inclu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government